Please assess the completion status of the following clinical trial:

Trial Title: Study of the Immunogenicity and Safety of a Challenge Dose of HBVAXPRO in Healthy Children Vaccinated 10 Years Ago With 3 Doses of HEXAVAC or INFANRIX HEXA

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy child~* Child vaccinated with 3 doses of HEXAVAC or 3 doses of INFANRIX HEXA as infant~* Child vaccinated with the third dose of HEXAVAC or INFANRIX HEXA at least 10 years prior to challenge dose~Exclusion Criteria:~* Receipt of more than 3 doses of any Hepatitis B containing vaccine~* History of clinical diagnosis of infection due to Hepatitis B~* History or current close contact with known carriers of Hepatitis B virus~* Prior known sensitivity or allergy to any component of HBVAXPRO~* Chronic illness / medical condition that could interfere with study conduct or completion~* Coagulation disorder that would contraindicate intramuscular injection~* Subject is pregnant~* Receipt of corticosteroids for more than 14 days in the 30 days prior to study~* Receipt of Immunoglobulins, blood or blood-derived products in the 3 months prior to study~* Planned participation in another clinical study

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: 12 Years
- Healthy Volunteers: t

Study Arms:
- HBVAXPRO Challenge dose (Type: EXPERIMENTAL): HBVAXPRO 5µg

Based on this trial design, predict the completion outcome and termination type (if applicable).